This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain momentum from robust medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.
The Zacks Analyst Blog Highlights McKesson, Corteva, Atmos Energy and National Fuel Gas
by Zacks Equity Research
McKesson, Corteva, Atmos Energy and National Fuel Gas are part of the Zacks top Analyst Blog.
3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why Investors Should Hold Myriad Genetics (MYGN) Now
by Zacks Equity Research
Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
by Zacks Equity Research
The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
4 Top-Ranked Defensive Stocks to Buy Amid Market Swings
by Snehadri Nag
Here we mention four defensive stocks, namely Corteva (CTVA), Atmos Energy, National Fuel Gas Company and McKesson with strong prospects to beat the market whims.
McKesson (MCK) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $343.27 in the latest trading session, marking a -1.06% move from the prior day.
3 Medical Stocks Displaying Remarkable Relative Strength in 2022
by Derek Lewis
In addition to favorable price action, all three carry a strong growth profile, making them appear even more enticing.
Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod
by Zacks Equity Research
Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.
Bruker (BRKR) Gains From New Product Bookings Amid Competition
by Zacks Equity Research
Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.
Walgreens Boots' (WBA) Product Expansion Aids Amid Rivalry
by Zacks Equity Research
Sales contributions from Walgreens Boots' (WBA) newly-formed Walgreens Health segment instill investors' optimism.
Here's Why Investors Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.
PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance
by Zacks Equity Research
PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
The Zacks Analyst Blog Highlights NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson
by Zacks Equity Research
NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson are included in this Analyst Blog.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.
Abbott (ABT) Reports Favorable Findings From RELIEF Study
by Zacks Equity Research
The latest data from the RELIEF Study suggests a lower rate of hospitalizations from serious diabetes-related events with Abbott's (ABT) FreeStyle Libre system.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and solid prospects in the RCM space raise optimism about the stock.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Medtronic (MDT) Gets FDA's 510(k) Nod for Pediatric ICM
by Zacks Equity Research
This latest approval broadens Medtronic's scope within its Cardiovascular Diagnostics and Services wing within broader Cardiovascular business.
Bet on These 5 Ultra-Defensive Stocks for the Rest of 2022
by Nalak Das
We have narrowed our search to five low-beta high-yielding defensive stocks that have strong potential for the rest of 2022. These are: NEE, SO, PEP, CTVA and MCK.
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
by Zacks Equity Research
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.